Cargando…

Multiresistant bacteria and current therapy - the economical side of the story

Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been identified. Remarkably drug acquisition costs are not necessar...

Descripción completa

Detalles Bibliográficos
Autor principal: Wilke, MH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352106/
https://www.ncbi.nlm.nih.gov/pubmed/21163732
http://dx.doi.org/10.1186/2047-783X-15-12-571
_version_ 1782232849368219648
author Wilke, MH
author_facet Wilke, MH
author_sort Wilke, MH
collection PubMed
description Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been identified. Remarkably drug acquisition costs are not necessarily included. Most significant are the length of stay in hospital, the hours of mechanical ventilation and the time treated on an intensive care unit. In a systematic review of the literature the following aspects were investigated: - Do generic treatment strategies contribute in cost savings? - Are there specific results for recent antibiotics? Early adequate and effective antimicrobial treatment, switch from i.v. to oral therapy, adjusted duration of therapy and adherence to guidelines have been found to be successful strategies. Looking at specific antibiotics, the best evidence for cost-effectiveness is found for Linezolid in treatment of cSSTI as well as in HAP. Daptomycin shows good economic results in bloodstream infections, so possibly being a cost-effective alternative to vancomycin. Looking at tigecycline the published data show neither higher costs nor savings compared to imipeneme. Doripenem as one of the newest therapy options has proven to be highly cost-saving in HAP when compared with imipenem. However, most analyses are based on pharmacoeconomic modelling rather than on directly analysing trial data or real life clinical populations. CONCLUSION: Using modern antibiotics in whole is not more expensive than using established therapies. Modern antibiotics are cost-effective and sometimes even cost-saving. This is especially true if an effective therapy is initiated as early as possible.
format Online
Article
Text
id pubmed-3352106
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33521062012-05-16 Multiresistant bacteria and current therapy - the economical side of the story Wilke, MH Eur J Med Res Research Severe infections with multiresistant bacteria (MRB) are a medical challenge and a financial burden for hospitals. The adequate antibiotic therapy is a key issue in multiresistant bacteria management. Several major cost drivers have been identified. Remarkably drug acquisition costs are not necessarily included. Most significant are the length of stay in hospital, the hours of mechanical ventilation and the time treated on an intensive care unit. In a systematic review of the literature the following aspects were investigated: - Do generic treatment strategies contribute in cost savings? - Are there specific results for recent antibiotics? Early adequate and effective antimicrobial treatment, switch from i.v. to oral therapy, adjusted duration of therapy and adherence to guidelines have been found to be successful strategies. Looking at specific antibiotics, the best evidence for cost-effectiveness is found for Linezolid in treatment of cSSTI as well as in HAP. Daptomycin shows good economic results in bloodstream infections, so possibly being a cost-effective alternative to vancomycin. Looking at tigecycline the published data show neither higher costs nor savings compared to imipeneme. Doripenem as one of the newest therapy options has proven to be highly cost-saving in HAP when compared with imipenem. However, most analyses are based on pharmacoeconomic modelling rather than on directly analysing trial data or real life clinical populations. CONCLUSION: Using modern antibiotics in whole is not more expensive than using established therapies. Modern antibiotics are cost-effective and sometimes even cost-saving. This is especially true if an effective therapy is initiated as early as possible. BioMed Central 2010-11-30 /pmc/articles/PMC3352106/ /pubmed/21163732 http://dx.doi.org/10.1186/2047-783X-15-12-571 Text en Copyright ©2010 I. Holzapfel Publishers
spellingShingle Research
Wilke, MH
Multiresistant bacteria and current therapy - the economical side of the story
title Multiresistant bacteria and current therapy - the economical side of the story
title_full Multiresistant bacteria and current therapy - the economical side of the story
title_fullStr Multiresistant bacteria and current therapy - the economical side of the story
title_full_unstemmed Multiresistant bacteria and current therapy - the economical side of the story
title_short Multiresistant bacteria and current therapy - the economical side of the story
title_sort multiresistant bacteria and current therapy - the economical side of the story
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352106/
https://www.ncbi.nlm.nih.gov/pubmed/21163732
http://dx.doi.org/10.1186/2047-783X-15-12-571
work_keys_str_mv AT wilkemh multiresistantbacteriaandcurrenttherapytheeconomicalsideofthestory